REPLIGEN CORP (RGEN)       180.96  +1.63 (+0.91%)

180.96  +1.63 (+0.91%)

US7599161095 - Common Stock - After market: 180.96 0 (0%)

News Image
6 days ago - Market News Video

Repligen (RGEN) Shares Cross Below 200 DMA

News Image
9 days ago - Repligen Corporation

Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement

Signs 15-year Strategic Collaboration and Exclusive License Agreement...

News Image
12 days ago - MarketBeat

MarketBeat: Week in Review 9/12 – 9/16

In volatile markets, rely on MarketBeat to keep you focused on your investment objectives. Here are some of our most popular articles from this week

News Image
13 days ago - MarketBeat

Why Medical Products Maker Repligen May Be A Potential Buy

Medical products maker Repligen has a long history of trouncing sales and earnings views, and it just boosted its full-year sales guidance. Is the stock a buy?

News Image
a month ago - Investor's Business Daily

Top-Rated Stocks: Lantheus Stock Sees Composite Rating Climb To 96

Top-rated Lantheus stock saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96.

News Image
a month ago - Repligen Corporation

Repligen To Host Investor Day 2022

WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions,...

News Image
a month ago - Investor's Business Daily

Glaukos Stock Scores Rising Price Performance With Jump To 91 RS Rating

On Tuesday, Glaukos stock hit an key technical milestone, with its Relative Strength Rating climbing to 91, up from 87 the day before.

News Image
2 months ago - Investor's Business Daily

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

News Image
2 months ago - Repligen Corporation

Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance

Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year)Strong...

News Image
2 months ago - Investor's Business Daily

Silk Road Medical Stock Clears Key Benchmark, Hitting 90-Plus RS Rating

Silk Road Medical stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 90.

News Image
2 months ago - Repligen Corporation

Repligen to Report Second Quarter 2022 Financial Results

Webcast and Conference Call to Be Held Tuesday, August 2, 2022 at 8:30 a.m. EDT...

News Image
4 months ago - Repligen Corporation

Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of...

News Image
4 months ago - Repligen Corporation

Repligen Corporation to Present at Upcoming Investor Conferences

WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...